We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Dr. Manuel Comabella and Dr. Sunny Malhotra have been recognized by Fundación Merck Salud for their research on prognostic factors for multiple sclerosis.
December 18 is National Multiple Sclerosis Day. To commemorate it, Fundación Merck Salud awards the Multiple Sclerosis Solidarity Awards, which this year reach their fifth edition. On this occasion, the recognitions, which have the social support of the Spanish Neurology Society, have been announced within the framework of EFE Health Forum. Among the winners, this year are Dr. Manuel Comabella, from the Clinical Neuroimmunology Service at the Vall d’Hebron University Hospital, head of the Clinical Neuroimmunology laboratory at the Vall d’Hebron Research Institute (VHIR) and head of laboratory at the Multiple Sclerosis Centre of Catalonia (Cemcat); and Dr. Sunny Malhotra, researcher at the Clinical Neuroimmunology group at VHIR and Cemcat.
The MS Solidarity Awards are aimed at the ideas, people or projects that have been the most valued or recognized within the world of multiple sclerosis nationally this year. The awards have two categories, collective and individual, being in the latter where the Vall d’Hebron researchers have received recognition as professionals who, with their efforts, work to help people with multiple sclerosis.
Specifically, researchers have been awarded for their research, which aims to identify prognostic biomarkers for multiple sclerosis with the potential to become therapeutic targets. Among them, they have identified two factors (IL1B and NLRP3) in patients with primary progressive multiple sclerosis, a clinical form with a greater degenerative component for which the therapeutic arsenal is currently limited.
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to email@example.com, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.